ORRF presents a stark contradiction between deep value and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the stock trades at a significant discount to its Graham Number ($53.4) and Intrinsic Value ($123.31), the low health score and bearish insider activity (CEO selling) suggest underlying risks. These concerns are offset by an exceptional earnings track record and explosive YoY earnings growth of 55.9%. Consequently, the stock is a high-reward value play tempered by significant fundamental red flags.